Atrial Fibrillation
Conditions
Keywords
atrial fibrillation, inappropriate shock, AV-node stimulation, ventricular arrhythmia
Brief summary
The aim of this multi-center research study is to evaluate the performance (primary purpose) and safety of a new algorithm aimed at controlling ventricular rate (VR) during rapidly conducted atrial fibrillation (AF) by delivering AV node stimulation (AVNS) from the atrial lead placed at a septal position, and designed with the purpose of reducing inappropriate shocks. Additional purposes include the assessment of a possible application of AVNS aimed at allowing prolonged control of VR during AF and reducing AF symptoms, and evaluation of implantation data on selective placement of the atrial lead in postero-septal right atrium. About 37 patients will be followed for half a year.
Detailed description
The aim of this multi-center research study is to evaluate the performance (primary purpose) and safety of a new algorithm aimed at controlling VR during rapidly conducted AF by delivering AVNS from the atrial lead placed at a septal position, and designed with the purpose of reducing inappropriate shocks. Additional purposes include the assessment of a possible application of AVNS aimed at allowing prolonged control of VR during AF and reducing AF symptoms, and evaluation of implantation data on selective placement of the atrial lead in postero-septal right atrium. About 37 patients will be followed for half a year.
Interventions
DEVICEAVNS ON
Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
Sponsors
Medtronic BRC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a documented history of paroxysmal or persistent AF are eligible to be enrolled in the study if one of the following criteria is met: * Indication for CRT implant according to current Guidelines (Heart Failure, NYHA III-IV class, symptomatic despite optimal stable medical therapy, left ventricular (LV) ejection fraction ≤35% and QRS≥120ms); OR * Indication for upgrading to CRT-D from a single chamber device; OR * Indication for upgrading to CRT-D from a dual chamber device with septal atrial lead or a dislodged atrial lead; OR * Indication for device replacement or surgical revision in patients already implanted with a CRT-D device and an atrial lead in the septal position or a dislodged atrial lead; OR * Patients already implanted with a ConsultaTM device and an atrial lead in the septal position, requiring electrical cardioversion.
Exclusion criteria
* If any of the following criteria are met, patient cannot be enrolled in the study: * Permanent atrial fibrillation; * Patients who are not on anti-coagulant therapy; * Advanced AV block (II-III degree AV block); * Patients previously submitted to valvular surgery; * Patients previously submitted to AV or AF ablative procedures; * Age \< 18 years; * Patient not disposed to sign the Informed Consent; * Participation in other studies which could potentially conflict with this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the performance of the investigational algorithm in reducing mean VR during AF, the relative reduction of VR during AVNS will be assessed in acute in-hospital tests, conducted preferably during either spontaneous or induced episodes of AF. | baseline and 1 month |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the performance of the investigational algorithm in shock reduction. | baseline, 1 month, 3 months, 6 months | assessing the number of successful rate reduction interventions by AVNS during spontaneous episodes of AF occurring during follow-up, with rapid VR due to AF conducted in the VT/FVT/VF zone; |
| To evaluate the safety of the investigational algorithm. | baseline, 1 month, 3 months, 6 months | To evaluate the safety of the investigational algorithm, assessing: * The rate of adverse device effects and serious adverse device effects related to the investigational algorithm; * The number of VT/VF or AT/AF episodes potentially induced or prolonged by the investigational algorithm. |
| To gather data for further possible applications. | baseline, 1 month, 3 months, 6 months | To gather data for further possible applications of AVNS, assessing: * the performance of the investigational algorithm in decreasing mean VR and standard deviation directly after 30 seconds of AVNS as compared to 30 seconds directly before algorithm intervention (baseline: all patients; 1, 3 and 6 months follow-up: patients in AF only); * the performance of the investigational algorithm in combination with ventricular pacing in decreasing mean VR and standard deviation directly after 30 seconds of AVNS as compared to 30 seconds directly before algorithm intervention (baseline only). |
| To collect data on selective placement of the atrial lead. | baseline, 1 month, 3 months, 6 months | evaluating: * electrical characteristics (impedance, threshold, sensing, FFRW) related to pacing and AVNS at implant (when applicable), baseline and follow-ups; * the percentage of atrial lead implantations with electrical characteristics suitable both for standard pacing and AVNS; * adverse events related to selective atrial lead placement at implant and in the follow-up; * mean duration of implant procedure and mean fluoroscopic time; * the presence of an implant learning curve. |
Countries
Germany, Italy, Sweden
Outcome results
None listed